The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2020 Apr 14

DOI: 10.23736/S1824-4785.20.03238-0

Copyright © 2020 EDIZIONI MINERVA MEDICA

lingua: Inglese

Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors

Fiona OHLENDORF ¹, Christoph HENKENBERENS ², Thomas BRUNKHORST ¹, Tobias L. ROSS ¹, Hans CHRISTIANSEN ², Frank M. BENGEL ¹, Thorsten DERLIN ¹ ✉

¹ Department of Nuclear Medicine, Hannover Medical School, Hannover, Germany; ² Department of Radiation Oncology, Hannover Medical School, Hannover, Germany

BACKGROUND: A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic neuroendocrine tumors, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated volumetric parameters for quantification of whole-body tumor burden from somatostatin receptor (SSR)- targeted PET/CT.
METHODS: 32 patients with metastastic grade1/grade 2 gastroenteropancreatic neuroendocrine tumors who underwent a 68Ga-DOTA-TATE PET/CT for staging of disease before initiation of peptide receptor radionuclide therapy were included in this retrospective cohort analysis. Volumetric parameters of tumor lesions, SSR-derived tumor volume (SSR-TV) and total lesion SSR (TL-SSR), were calculated for each patient using a computerized volumetric technique with a 40% SUVmax cut-off, and compared with serum chromogranin A (CgA) levels. Progression-free survival (PFS) was determined in relation to volumetric parameters. In a subgroup of 18 patients, the feasibility of volumetric parameters for treatment monitoring was evaluated.
RESULTS: Mean SSR-TV was 178±214 cm3 (range, 9-797 cm3), whereas mean TL-SSR was 4096±5191 cm3 (range, 61-19203 cm3). Baseline CgA levels were associated with whole- body tumor burden (SSR-TV, r=0.57, P=0.0008; and TL-SSR, r=0.43, P=0.01, respectively). PFS was shorter in patients with high SSR-TV and high TL-SSR (HR 5.16 (95% CI, 1.61- 29.67), P=0.009), and SSR-TV (P = 0.0067) and TL-SSR (P = 0.0215) emerged as the sole predictors of progression in regression analysis. Changes in CgA did not correctly identify treatment response (P=0.25).
CONCLUSIONS: SSR-derived volumetric parameters provide a quantitative imaging biomarker for whole-body tumor burden, and may hold potential as a clear-cut measure for assessment of treatment response.

KEY WORDS: Somatostatin receptor; PET/CT; Tumor volume; DOTA-TATE; Radionuclide therapy